Pharmacological management of cerebral ischemia in the elderly

References

• Heron M. Deaths: leading causes for 2017. Natl Vital Stat Rep. 2019 Jun;68(6):1–77.
   PubMedGoogle Scholar
• Saposnik G, Cote R, Phillips S, et al. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008 Aug;39(8):2310–2317.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the american heart association. Circulation. 2019 Mar 5;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Christophe BR, Mehta SH, Garton AL, et al. Current and future perspectives on the treatment of cerebral ischemia. Expert Opin Pharmacother. 2017 Apr;18(6):573–580.
   PubMed Web of Science ®Google Scholar
• Petcu EB, Sfredel V, Platt D, et al. Cellular and molecular events underlying the dysregulated response of the aged brain to stroke: a mini-review. Gerontology. 2008;54(1):6–17.
   PubMed Web of Science ®Google Scholar
• Popa-Wagner A, Dinca I, Yalikun S, et al. Accelerated delimitation of the infarct zone by capillary-derived nestin-positive cells in aged rats. Curr Neurovasc Res. 2006 Feb;3(1):3–13.
   PubMed Web of Science ®Google Scholar
• Badan I, Platt D, Kessler C, et al. Temporal dynamics of degenerative and regenerative events associated with cerebral ischemia in aged rats. Gerontology. 2003 Nov-Dec;49(6):356–365.
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu Q, Anrather J, et al. Immune interventions in stroke. Nat Rev Neurol. 2015 Sep;11(9):524–535.
   PubMed Web of Science ®Google Scholar
• Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets. 2008 Feb;12(2):159–170.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Rabinstein AA, Ackerson T, et al. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018 Mar;49(3):e46–e110.
   PubMed Web of Science ®Google Scholar
• Lees KR, Emberson J, Blackwell L, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 Trials. Stroke. 2016 Sep;47(9):2373–2379.
   PubMed Web of Science ®Google Scholar
• Yayan J. Effectiveness of alteplase in the very elderly after acute ischemic stroke. Clin Interv Aging. 2013;8:963–974.
   PubMed Web of Science ®Google Scholar
• Reuter B, Gumbinger C, Sauer T, et al. Intravenous thrombolysis for acute ischaemic stroke in the elderly: data from the baden-wuerttemberg stroke registry. Eur J Neurol. 2016 Jan;23(1):13–20.
   PubMed Web of Science ®Google Scholar
• von Kummer R, Mori E, Truelsen T, et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke). Stroke. 2016 Dec;47(12):2880–2887.
   PubMed Web of Science ®Google Scholar
• Albers GW, von Kummer R, Truelsen T, et al. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015 Jun;14(6):575–584.
   PubMed Web of Science ®Google Scholar
• A randomized controlled trial of TNK-tPA versus standard of care for minor ischemic stroke with proven occlusion. https://ClinicalTrials.gov/show/NCT02398656 [Last accessed 11 November 2020]
   Google Scholar
• The Norwegian tenecteplase stroke trial 2. https://ClinicalTrials.gov/show/NCT03854500 [Last accessed 11 November 2020]
   Google Scholar
• Kheiri B, Osman M, Abdalla A, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018 Nov;46(4):440–450.
   PubMed Web of Science ®Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018 Apr 26;378(17):1573–1582.
   PubMed Web of Science ®Google Scholar
• Study of rhPro-UK in patients with acute ischaemic stroke in 4.5 hours after stroke onset(PROST). https://ClinicalTrials.gov/show/NCT03541668 [Last accessed 11 November 2020]
   Google Scholar
• O’Sullivan ED, Hughes J, Ferenbach DA. Renal Aging: causes and Consequences. J Am Soc Nephrol. 2017 Feb;28(2):407–420.
   PubMed Web of Science ®Google Scholar
• Ninomiya T. Risk of stroke in kidney disease. Contrib Nephrol. 2013;179:58–66.
   PubMed Web of Science ®Google Scholar
• Mtwesi V, Amit G. Stroke prevention in atrial fibrillation: the role of oral anticoagulation. Med Clin North Am. 2019 Sep;103(5):847–862.
   PubMed Web of Science ®Google Scholar
• Jung JM, Kim HJ, Ahn H, et al. Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis. J Neurol Sci. 2015 Nov 15;358(1–2):345–350.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Forbes WP, Bramer SL. Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites. Clin Pharmacokinet. 1999;37(Suppl 2):33–40.
   PubMedGoogle Scholar
• Oza R, Rundell K, Garcellano M. Recurrent ischemic stroke: strategies for prevention. Am Fam Physician. 2017 Oct 1;96(7):436–440.
   PubMed Web of Science ®Google Scholar
• Balinski AM, Preuss CV. Cilostazol. StatPearls. Treasure Island (FL): StatPearls Publishing; Copyright ©. 2020, StatPearls Publishing LLC. 2020.
   Google Scholar
• Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis. 2000 Jul-Aug;9(4):147–157.
   PubMedGoogle Scholar
• Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol. 2010 Oct;9(10):959–968.
   PubMed Web of Science ®Google Scholar
• Pan H, Boucher M, Kaunelis D. PAR-1 antagonists: an emerging antiplatelet drug class. CADTH issues in emerging health technologies. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; Copyright © CADTH. 2016.
   Google Scholar
• Baker NC, Lipinski MJ, Lhermusier T, et al. Overview of the 2014 food and drug administration cardiovascular and renal drugs advisory committee meeting about vorapaxar. Circulation. 2014 Oct 7;130(15):1287–1294.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012 Apr 12;366(15):1404–1413.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Scirica BM, Braunwald E, et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014 Dec 9;64(22):2318–2326.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Alberts MJ, Mohr JP, et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013 Mar;44(3):691–698.
   PubMed Web of Science ®Google Scholar
• Correa S, Bonaca MP, Scirica BM, et al. Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr;47(3):353–360.
   PubMed Web of Science ®Google Scholar
• Lionakis N, Mendrinos D, Sanidas E, et al. Hypertension in the elderly. World J Cardiol. 2012 May 26;4(5):135–147.
   PubMedGoogle Scholar
• Abraham HM, White CM, White WB. The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases. Drug Saf. 2015 Jan;38(1):33–54.
   PubMed Web of Science ®Google Scholar
• Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011 Feb 26;377(9767):741–750.
   PubMed Web of Science ®Google Scholar
• Jusufovic M, Sandset EC, Bath PM, et al. Early blood pressure lowering treatment in acute stroke. Ordinal analysis of vascular events in the scandinavian candesartan acute stroke trial (SCAST). J Hypertens. 2016 Aug;34(8):1594–1598.
   PubMed Web of Science ®Google Scholar
• Sandset EC, Jusufovic M, Sandset PM, et al. Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. Stroke. 2015 Mar;46(3):877–879.
   PubMed Web of Science ®Google Scholar
• Ay H, Koroshetz WJ, Vangel M, et al. Conversion of ischemic brain tissue into infarction increases with age. Stroke. 2005 Dec;36(12):2632–2636.
   PubMed Web of Science ®Google Scholar
• Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the perindopril protection against recurrent stroke study trial. Hypertension. 2010 May;55(5):1193–1198.
   PubMed Web of Science ®Google Scholar
• Bonnin P, Mazighi M, Charriaut-Marlangue C, et al. Early collateral recruitment after stroke in infants and adults. Stroke. 2019 Sep;50(9):2604–2611.
   PubMed Web of Science ®Google Scholar
• Kamel H, Healey JS. Cardioembolic Stroke. Circ Res. 2017 Feb 3;120(3):514–526.
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–867.
   PubMed Web of Science ®Google Scholar
• Reed D, Palkimas S, Hockman R, et al. Safety and effectiveness of apixaban compared to warfarin in dialysis patients. Res Pract Thromb Haemost. 2018 Apr;2(2):291–298.
   PubMed Web of Science ®Google Scholar
• Amantea D, Greco R, Micieli G, et al. Paradigm shift to neuroimmunomodulation for translational neuroprotection in stroke. Front Neurosci. 2018;12:241.
   PubMed Web of Science ®Google Scholar
• Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003;15(3):222–229.
   PubMed Web of Science ®Google Scholar
• Kono S, Deguchi K, Morimoto N, et al. Intravenous thrombolysis with neuroprotective therapy by edaravone for ischemic stroke patients older than 80 years of age. J Stroke Cerebrovasc Dis. 2013 Oct;22(7):1175–1183.
   PubMed Web of Science ®Google Scholar
• Kimura K, Aoki J, Sakamoto Y, et al. Administration of edaravone, a free radical scavenger, during t-PA infusion can enhance early recanalization in acute stroke patients–a preliminary study. J Neurol Sci. 2012 Feb .;313(1–2):132–136.
   PubMed Web of Science ®Google Scholar
• Hishida A. Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol. 2007 Dec;11(4):292–296.
   PubMedGoogle Scholar
• Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010 Jul;11(10):1753–1763.
   PubMed Web of Science ®Google Scholar
• Pawluk H, Woźniak A, Grześk G, et al. The role of selected pro-inflammatory cytokines in pathogenesis of ischemic stroke. Clin Interv Aging. 2020;15:469–484.
   PubMed Web of Science ®Google Scholar
• Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. 2012 Sep;32(9):1677–1698.
   PubMed Web of Science ®Google Scholar
• Rothwell N. Interleukin-1 and neuronal injury: mechanisms, modification, and therapeutic potential. Brain Behav Immun. 2003 Jun;17(3):152–157.
   PubMed Web of Science ®Google Scholar
• McCann SK, Cramond F, Macleod MR, et al. Systematic review and meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update. Transl Stroke Res. 2016 Oct;7(5):395–406.
   PubMed Web of Science ®Google Scholar
• Smith CJ, Hulme S, Vail A, et al. SCIL-STROKE (subcutaneous interleukin-1 receptor antagonist in ischemic stroke): a randomized controlled phase 2 trial. Stroke. 2018 May;49(5):1210–1216.
   PubMed Web of Science ®Google Scholar
• Nelson SM, Nguyen TM, McDonald JW, et al. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2018 Aug 1;8(8):Cd006097.
   PubMedGoogle Scholar
• Delbue S, Comar M, Ferrante P. Natalizumab treatment of multiple sclerosis: new insights. Immunotherapy. 2017 Jan;9(2):157–171.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004 Jul;4(4):571–580.
   PubMedGoogle Scholar
• Elkins J, Veltkamp R, Montaner J, et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017 Mar;16(3):217–226.
   PubMed Web of Science ®Google Scholar
• Elkind MSV, Veltkamp R, Montaner J, et al. Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial. Neurology. 2020 Aug 25;95(8):e1091–e104.
   PubMed Web of Science ®Google Scholar
• Drieu A, Buendia I, Levard D, et al. Immune responses and anti-inflammatory strategies in a clinically relevant model of thromboembolic ischemic stroke with reperfusion. Transl Stroke Res. 2020 Jun;11(3):481–495.
   PubMed Web of Science ®Google Scholar
• Tatlisumak T. Can natalizumab be beneficial in acute ischaemic stroke? Lancet Neurol. 2017 Mar;16(3):176–177.
   PubMed Web of Science ®Google Scholar
• Ao LY, Yan YY, Zhou L, et al. Immune cells after ischemic stroke onset: roles, migration, and target intervention. J Mol Neurosci. 2018 Nov;66(3):342–355.
   PubMed Web of Science ®Google Scholar
• Tymianski M. Combining neuroprotection with endovascular treatment of acute stroke: is there hope? Stroke. 2017 Jun;48(6):1700–1705.
   PubMed Web of Science ®Google Scholar
• Shi L, Rocha M, Leak RK, et al. A new era for stroke therapy: integrating neurovascular protection with optimal reperfusion. J Cereb Blood Flow Metab. 2018 Dec;38(12):2073–2091.
   PubMed Web of Science ®Google Scholar
• Montaner J, Bustamante A, García-Matas S, et al. Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial (stroke treatment with acute reperfusion and simvastatin). Stroke. 2016 Nov;47(11):2870–2873.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Wiviott SD, Giugliano RP, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). Circulation. 2017 Dec 19;136(25):2440–2450.
   PubMed Web of Science ®Google Scholar
• Muscari A, Puddu GM, Santoro N, et al. The atorvastatin during ischemic stroke study: a pilot randomized controlled trial. Clin Neuropharmacol. 2011 Jul-Aug;34(4):141–147.
   PubMed Web of Science ®Google Scholar
• Amarenco P. Atorvastatin in prevention of stroke and transient ischaemic attack. Expert Opin Pharmacother. 2007 Nov;8(16):2789–2797.
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang X, Dong L, et al. The many roles of statins in ischemic stroke. Curr Neuropharmacol. 2014 Dec;12(6):564–574.
   PubMed Web of Science ®Google Scholar
• Zhang L, Chopp M, Lu M, et al. Cerebrolysin dose-dependently improves neurological outcome in rats after acute stroke: A prospective, randomized, blinded, and placebo-controlled study. Int J Stroke. 2016 Apr;11(3):347–355.
   PubMed Web of Science ®Google Scholar
• Ziganshina LE, Abakumova T, Vernay L. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2017 Apr 21;4(4):Cd007026.
   PubMedGoogle Scholar
• Zhang D, Dong Y, Li Y, et al. Efficacy and safety of cerebrolysin for acute ischemic stroke: a meta-analysis of randomized controlled trials. Biomed Res Int. 2017;2017:4191670.
   PubMed Web of Science ®Google Scholar
• Hill MD, Goyal M, Menon BK, et al. Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial. Lancet. 2020 Mar 14;395(10227):878–887.
   PubMed Web of Science ®Google Scholar
• Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol. 2016 Dec 23;63(S03):S1–s73.
   PubMedGoogle Scholar
• Dávalos A, Alvarez-Sabín J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012 Jul 28;380(9839):349–357.
   PubMed Web of Science ®Google Scholar
• Secades JJ, Alvarez-Sabín J, Castillo J, et al. Citicoline for acute ischemic stroke: a systematic review and formal meta-analysis of randomized, double-blind, and placebo-controlled trials. J Stroke Cerebrovasc Dis. 2016 Aug;25(8):1984–1996.
   PubMed Web of Science ®Google Scholar
• Overgaard K. The effects of citicoline on acute ischemic stroke: a review. J Stroke Cerebrovasc Dis. 2014 Aug;23(7):1764–1769.
   PubMed Web of Science ®Google Scholar
• de Ridder IR, den Hertog HM, van Gemert HM, et al. PAIS 2 (paracetamol [acetaminophen] in stroke 2): results of a randomized, double-blind placebo-controlled clinical trial. Stroke. 2017 Apr;48(4):977–982.
   PubMed Web of Science ®Google Scholar
• Chen H, Qian H, Gu Z, et al. Temperature management with paracetamol in acute stroke patients: evidence from randomized controlled trials. Front Neurol. 2018;9:917.
   PubMed Web of Science ®Google Scholar
• Reith J, Jørgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996 Feb 17;347(8999):422–425.
   PubMed Web of Science ®Google Scholar
• Reinink H, de Jonge JC, Bath PM, et al. PRECIOUS: prevention of complications to improve outcome in elderly patients with acute stroke. rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. Eur Stroke J. 2018 Sep;;3(3):291–298.
   PubMed Web of Science ®Google Scholar
• Gillies PS, Dunn CJ. Pioglitazone. Drugs. 2000 Aug;60(2):333–343. discussion 44–5.
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Furie KL. The IRIS (insulin resistance intervention after stroke) trial: A new perspective on pioglitazone. J Diabetes. 2016 Sep;8(5):607–609.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Viscoli CM, Furie KL, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016 Apr 7;374(14):1321–1331.
   PubMed Web of Science ®Google Scholar
• Zinman B, Inzucchi SE, Lachin JM, et al. Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk. Stroke. 2017 May;48(5):1218–1225.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Lindley RI, Rådholm K, et al. Canagliflozin and stroke in type 2 diabetes mellitus. Stroke. 2019 Feb;50(2):396–404.
   PubMed Web of Science ®Google Scholar
• Popa-Wagner A, Buga AM, Doeppner TR, et al. Stem cell therapies in preclinical models of stroke associated with aging. Front Cell Neurosci. 2014;8:347.
   PubMed Web of Science ®Google Scholar
• Sandu RE, Dumbrava D, Surugiu R, et al. Cellular and molecular mechanisms underlying non-pharmaceutical ischemic stroke therapy in aged subjects. Int J Mol Sci. 2017 Dec 29;19:1.
   Web of Science ®Google Scholar
• Popa-Wagner A, Dumitrascu DI, Capitanescu B, et al. Dietary habits, lifestyle factors and neurodegenerative diseases. Neural Regen Res. 2020 Mar;15(3):394–400.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang G, Zhang H, et al. Hypothalamic IKKbeta/NF-kappaB and ER stress link overnutrition to energy imbalance and obesity. Cell. 2008 Oct 3;135(1):61–73.
   PubMed Web of Science ®Google Scholar
• Piironen K, Tiainen M, Mustanoja S, et al. Mild hypothermia after intravenous thrombolysis in patients with acute stroke: a randomized controlled trial. Stroke. 2014 Feb;45(2):486–491.
   PubMed Web of Science ®Google Scholar
• van der Worp HB, Macleod MR, Bath PM, et al. EuroHYP-1: European multicenter, randomized, phase III clinical trial of therapeutic hypothermia plus best medical treatment vs. best medical treatment alone for acute ischemic stroke. Int J Stroke. 2014 Jul;9(5):642–645.
   PubMed Web of Science ®Google Scholar